| KAYSER, S., M. A. ELLIOTT, M. LUSKIN, A. M. BRUNNER, M. KRAMER, Zdeněk RÁČIL, Zuzana NOVÁKOVÁ, P. CETKOVSKY, J. NOVAK, F. STOELZEL, C. THIEDE, C. MULLER-TIDOW, U. PLATZBECKER, C. ROLLIG, R. F. SCHLENK a M. J. LEVIS. Characteristics and Outcome of Patients with Core Binding Factor Acute Myeloid Leukemia and FLT3-ITD: Results from an International Collaboration. ISSN 0006-4971. doi:10.1182/blood-2019-125317. 2019. |
Další formáty:
BibTeX
LaTeX
RIS
@proceedings{1718078,
author = {Kayser, S. and Elliott, M. A. and Luskin, M. and Brunner, A. M. and Kramer, M. and Ráčil, Zdeněk and Nováková, Zuzana and Cetkovsky, P. and Novak, J. and Stoelzel, F. and Thiede, C. and MullerandTidow, C. and Platzbecker, U. and Rollig, C. and Schlenk, R. F. and Levis, M. J.},
doi = {http://dx.doi.org/10.1182/blood-2019-125317},
keywords = {Core Binding Factor Acute Myeloid Leukemia; FLT3-ITD},
language = {eng},
title = {Characteristics and Outcome of Patients with Core Binding Factor Acute Myeloid Leukemia and FLT3-ITD: Results from an International Collaboration},
url = {https://ashpublications.org/blood/article/134/Supplement_1/2693/423109/Characteristics-and-Outcome-of-Patients-with-Core},
year = {2019}
}
TY - CONF
ID - 1718078
AU - Kayser, S. - Elliott, M. A. - Luskin, M. - Brunner, A. M. - Kramer, M. - Ráčil, Zdeněk - Nováková, Zuzana - Cetkovsky, P. - Novak, J. - Stoelzel, F. - Thiede, C. - Muller-Tidow, C. - Platzbecker, U. - Rollig, C. - Schlenk, R. F. - Levis, M. J.
PY - 2019
TI - Characteristics and Outcome of Patients with Core Binding Factor Acute Myeloid Leukemia and FLT3-ITD: Results from an International Collaboration
KW - Core Binding Factor Acute Myeloid Leukemia
KW - FLT3-ITD
UR - https://ashpublications.org/blood/article/134/Supplement_1/2693/423109/Characteristics-and-Outcome-of-Patients-with-Core
L2 - https://ashpublications.org/blood/article/134/Supplement_1/2693/423109/Characteristics-and-Outcome-of-Patients-with-Core
N2 - Core binding factor acute myeloid leukemia (CBF-AML) is defined by the presence of either t(8;21)(q22;q22) or inv(16)(p13.1q22)/t(16;16)(p13.1;q22) and is associated with a favorable outcome, particularly if treated with repetitive cycles of high-dose cytarabine as post-remission therapy. Long-time 10-year overall survival (OS) rate was reported of 58% in FLT3-ITD negative patients (pts; Allen et al. Leukemia 2013). Nevertheless, 30-40% CBF-AML pts experience relapse. FLT3-ITD mutations occur in roughly 5-10% of adult CBF-AML. However, their prognostic relevance is still controversial.
ER -
KAYSER, S., M. A. ELLIOTT, M. LUSKIN, A. M. BRUNNER, M. KRAMER, Zdeněk RÁČIL, Zuzana NOVÁKOVÁ, P. CETKOVSKY, J. NOVAK, F. STOELZEL, C. THIEDE, C. MULLER-TIDOW, U. PLATZBECKER, C. ROLLIG, R. F. SCHLENK a M. J. LEVIS. \textit{Characteristics and Outcome of Patients with Core Binding Factor Acute Myeloid Leukemia and FLT3-ITD: Results from an International Collaboration}. ISSN~0006-4971. doi:10.1182/blood-2019-125317. 2019.
|
